

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

**CLOSURE OF REGISTER OF MEMBERS FOR
2022 FIRST EXTRAORDINARY GENERAL MEETING**

The board of directors (the “**Board**”) of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) hereby announces that, for determining the list of shareholders of H shares (“**H Shares**”) of the Company who are entitled to attend and vote at the 2022 first extraordinary general meeting (the “**EGM**”), which is scheduled to be held on Thursday, May 5, 2022, the H Shares register of members will be closed from Thursday, April 28, 2022 to Thursday, May 5, 2022, both days inclusive. The shareholders of H Shares whose name appear on the register of members of the Company on Thursday, April 28, 2022 will be entitled to attend and vote at the EGM. During such period, no share transfers will be registered. In order to be eligible for attending and voting at the EGM, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Wednesday, April 27, 2022. A notice containing details of the resolution to be proposed at the EGM will be despatched to shareholders of the Company in due course.

By order of the Board

RemeGen Co., Ltd.*

Mr. Wang Weidong

Chairman and executive director

Yantai, The PRC

April 12, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

* For identification purposes only